Retatrutide has produced some of the largest average weight reductions yet reported for an investigational obesity drug, but the strongest published figure rests on phase 2 evidence, not the confirmatory phase 3 data regulators require. The most cited result, an average reduction near 24 percent of body weight at 48 weeks on the highest dose, comes from a defined-duration trial in a limited number of adults without diabetes, and it describes what a controlled study population experienced rather than a guaranteed outcome. Retatrutide is an investigational triple receptor agonist that is not FDA-approved as of mid-2026, so these numbers carry the usual caution that applies to phase 2 results.
A phase 2 obesity trial reported an average weight reduction of about 24 percent at 48 weeks on retatrutide's highest tested dose, in adults without diabetes, while the drug remains investigational and not FDA-approved as of mid-2026.
The number that circulates most often is an average reduction near 24 percent of body weight, recorded in participants on the highest dose at the 48-week mark of a phase 2 obesity trial. It is a group average rather than a guaranteed individual result, and the trial itself showed smaller losses at lower doses, so the headline figure marks the high end of what was observed rather than a uniform outcome.
The most-quoted retatrutide figure, an average reduction of about 24 percent of body weight, applies specifically to the highest dose at 48 weeks and represents a group mean at the top of the dose range rather than a per-person result.
The widely cited numbers come from a phase 2 study, which sits in the middle of the development pipeline and is built to test a range of doses and gather early efficacy and safety signals rather than to settle the question. It was a randomized, placebo-controlled trial in adults living with obesity, running roughly 48 weeks, and a result at this stage establishes a dose-response relationship without delivering the confirmation a phase 3 program provides.
The retatrutide weight loss figures come from a randomized, placebo-controlled phase 2 trial of roughly 48 weeks in adults with obesity, a design that establishes a dose-response signal but stops short of the phase 3 evidence required for FDA approval.
The trial showed a clear dose-dependent pattern: as the dose rose, average weight loss rose with it, the lowest doses producing modest reductions and the highest dose producing the figure near 24 percent. That orderly relationship is what investigators look for, because it strengthens the case that the drug itself is driving the change rather than chance or outside factors.
Retatrutide's weight loss in the phase 2 trial was clearly dose-dependent, rising from modest reductions at low doses to about 24 percent at the highest dose, with the top dose reached through gradual escalation rather than from the first injection.
Weight came off progressively across the 48-week trial rather than all at once, building steadily as the dose was escalated and maintained. The detail that draws the most attention is that the average weight-loss curve had not clearly leveled off by the end of the study, which is suggestive rather than conclusive, because the trial simply reached its scheduled endpoint and the data alone cannot show where the curve would eventually settle.
In the 48-week phase 2 trial, retatrutide's average weight-loss curve had not clearly plateaued by the study's end, which suggests but does not prove that further loss might have continued beyond the trial window.
Set against the figures published for approved single-target and dual-target incretin therapies in their own trials, retatrutide's phase 2 average sits at the higher end for this drug class, which is part of why it has drawn so much attention. The important caveat is that comparing numbers across separate trials is inherently imprecise, since different studies enroll different populations, run for different durations, and define their endpoints in their own ways, so a difference seen across unrelated trials is not the same as one proven head-to-head.
| Basis | Retatrutide (phase 2) | Approved incretin therapies (own trials) |
|---|---|---|
| Reported weight loss | Higher end for the class | Established but generally lower figures |
| Mechanism | Triple agonist: GIP, GLP-1, glucagon | Single-target or dual-target |
| Possible reason for difference | Glucagon component may raise energy expenditure alongside appetite effects | Appetite effects of one or two pathways |
| Evidence standing | Cross-trial inference only | Cross-trial inference only |
Retatrutide's phase 2 weight loss sits at the higher end of published figures for the incretin drug class, and its triple GIP, GLP-1, and glucagon mechanism offers a plausible reason why, but no head-to-head trial has confirmed an advantage over approved agents.
Several caveats keep the figures in perspective. The phase 2 study enrolled a limited number of participants and ran for a defined duration, so the averages carry more statistical uncertainty than larger phase 3 trials and say nothing definitive about multi-year results, and the controlled trial setting does not always match everyday use where adherence and circumstances vary.
Retatrutide's weight loss figures rest on a limited-sample, defined-duration phase 2 trial in an investigational drug that is not FDA-approved as of mid-2026, so larger and longer phase 3 trials could report figures that differ in either direction.
The headline figure is a population average that smooths over a wide spread of individual outcomes, where some participants lose considerably more than the mean and others much less, and a single number cannot capture that range. A real person's result is shaped by factors a trial average cannot hold, so the honest framing is that any individual should expect an outcome somewhere across a broad range rather than precisely on the reported figure.
Retatrutide's reported average reflects what a controlled study population experienced, so an individual's real-world result depends on starting weight, tolerated dose, consistency, and lifestyle, and lands somewhere across a broad range rather than on the headline figure.
Educational use only. This article describes what the published scientific and clinical literature reports about Retatrutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
